4D Pharma raises $40 million in a Nasdaq listing via a SPAC

Using a SPAC, 4D Pharma has listed shares on the Nasdaq.

CEO Duncan Peyton talks to IGTV about the deal, what it does and, now with US based drug company Merck as an interested party, through the listing, puts 4D Pharma (DDDD) into an interesting new position.